00:28 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Galderma planning Phase III program for atopic dermatitis therapy

Galderma said nemolizumab met the primary endpoint in a Phase IIb trial to treat adults with moderate-to-severe atopic dermatitis not adequately controlled by topical corticosteroids. The company plans to start a Phase III program of...
05:22 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Olumiant meets Phase III endpoints for atopic dermatitis

Eli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said Olumiant baricitinib met the primary endpoints of the Phase III BREEZE-AD1 and BREEZE-AD2 trials to treat moderate to severe atopic dermatitis. In the double-blind, international...
19:38 , Jan 16, 2019 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest adoptive transfer, or promoting the survival, of IgA-positive plasmablasts and plasma cells could help treat MS. In fecal samples from relapsing-remitting MS (RRMS) patients, counts...
19:37 , Jan 16, 2019 |  BC Innovations  |  Translation in Brief

Promoting gut plasmablasts for MS

Researchers from the University of Toronto and colleagues have linked the gut-brain axis to multiple sclerosis by showing gut plasmablasts and plasma cells suppress CNS inflammation during active MS, and suggested therapies that promote the...
21:19 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Tremfya superior to Cosentyx in head-to-head Phase III trial

Janssen Biotech Inc. said Tremfya guselkumab met the primary endpoint of improving PASI 90 response rate vs. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III ECLIPSE trial to treat moderate to severe...
18:25 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Sienna planning Phase III trials of pegcantratinib in psoriasis

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) plans to start Phase III trials in 2H19 of pegcantratinib (SNA-120) to treat psoriasis despite reporting that the compound missed the primary endpoint in a Phase IIb trial to treat pruritus...
18:24 , Nov 9, 2018 |  BC Week In Review  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Nov. 7 after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran...
17:57 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
23:29 , Nov 7, 2018 |  BC Extra  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and...
11:00 , Nov 7, 2018 |  BC Extra  |  Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...